American Association for Cancer Research
Browse
ccr-22-0822_supplementary_figure_s9_suppsf9.docx (134.13 kB)

Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19

Download (134.13 kB)
journal contribution
posted on 2023-03-31, 23:40 authored by Caroline Diorio, Rawan Shraim, Regina Myers, Edward M. Behrens, Scott Canna, Hamid Bassiri, Richard Aplenc, Chakkapong Burudpakdee, Fang Chen, Amanda M. DiNofia, Saar Gill, Vanessa Gonzalez, Michele P. Lambert, Allison Barz Leahy, Bruce L. Levine, Robert B. Lindell, Shannon L. Maude, J. Joseph Melenhorst, Haley Newman, Jessica Perazzelli, Alix E. Seif, Simon F. Lacey, Carl H. June, David M. Barrett, Stephan A. Grupp, David T. Teachey
Supplementary Figure from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19

Funding

NIH

Thrasher Research Fund

History

ARTICLE ABSTRACT

To study the biology and identify markers of severe cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in children after chimeric antigen receptor T-cell (CAR T) treatment. We used comprehensive proteomic profiling to measure over 1,400 serum proteins at multiple serial timepoints in a cohort of patients with B-cell acute lymphoblastic leukemia treated with the CD19-targeted CAR T CTL019 on two clinical trials. We identified fms-like tyrosine kinase 3 (FLT3) and mast cell immunoglobulin-like receptor 1 (MILR1) as preinfusion predictive biomarkers of severe CRS. We demonstrated that CRS is an IFNγ-driven process with a protein signature overlapping with hemophagocytic lymphohistiocytosis (HLH). We identified IL18 as a potentially targetable cytokine associated with the development of ICANS. We identified preinfusion biomarkers that can be used to predict severe CRS with a sensitivity, specificity, and accuracy superior to the current gold standard of disease burden. We demonstrated the fundamental role of the IFNγ pathway in driving CRS, suggesting CRS and carHLH are overlapping rather than distinct phenomena, an observation with important treatment implications. We identified IL18 as a possible targetable cytokine in ICANS, providing rationale for IL18 blocking therapies to be translated into clinical trials in ICANS.

Usage metrics

    Clinical Cancer Research

    Categories

    Keywords

    cancer

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC